BioCorRx Depreciation & Amortization Growth & History (BICX)
BioCorRx's depreciation and amortization was $44,003 for fiscal 2025.
View full BioCorRx company overviewBioCorRx annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $44,003 | $10,858 | +32.76% |
| 2024 | 2024-12-31 | $33,145 | $6,337 | +23.64% |
| 2023 | 2023-12-31 | $26,808 | −$642 | −2.34% |
| 2022 | 2022-12-31 | $27,450 | −$36,878 | −57.33% |
| 2021 | 2021-12-31 | $64,328 | −$12,926 | −16.73% |
| 2020 | 2020-12-31 | $77,254 | $47,841 | +162.65% |
| 2019 | 2019-12-31 | $29,413 | $22,060 | +300.01% |
| 2018 | 2018-12-31 | $7,353 | −$26,535 | −78.30% |
| 2017 | 2017-12-31 | $33,888 | $3,640 | +12.03% |
| 2016 | 2016-12-31 | $30,248 | −$94,822 | −75.82% |
| 2015 | 2015-12-31 | $125,070 | −$10,421 | −7.69% |
| 2014 | 2014-12-31 | $135,491 | −$23 | −0.02% |
| 2013 | 2013-12-31 | $135,514 | $133,526 | +6716.60% |
| 2012 | 2012-12-31 | $1,988 | −$203 | −9.27% |
| 2011 | 2011-12-31 | $2,191 | −$19,562 | −89.93% |
| 2010 | 2010-12-31 | $21,753 | — | — |
BioCorRx quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9,834 | −$62,143 | −86.34% |
| Q1 2026 | 2026-03-31 | $11,195 | −$13,648 | −54.94% |
| Q4 2025 | 2025-12-31 | −$114,489 | — | — |
| Q3 2025 | 2025-09-30 | $71,986 | $65,272 | +972.18% |
| Q2 2025 | 2025-06-30 | $71,977 | $65,263 | +972.04% |
| Q1 2025 | 2025-03-31 | $24,843 | $18,130 | +270.07% |
| Q3 2024 | 2024-09-30 | $6,714 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $6,714 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $6,713 | $48 | +0.72% |
| Q3 2023 | 2023-09-30 | $6,714 | −$149 | −2.17% |
| Q2 2023 | 2023-06-30 | $6,714 | −$148 | −2.16% |
| Q1 2023 | 2023-03-31 | $6,665 | −$198 | −2.89% |
| Q3 2022 | 2022-09-30 | $6,863 | −$11,884 | −63.39% |
| Q2 2022 | 2022-06-30 | $6,862 | −$12,478 | −64.52% |
| Q1 2022 | 2022-03-31 | $6,863 | −$12,515 | −64.58% |
| Q3 2021 | 2021-09-30 | $18,747 | −$422 | −2.20% |
| Q2 2021 | 2021-06-30 | $19,340 | $174 | +0.91% |
| Q1 2021 | 2021-03-31 | $19,378 | $207 | +1.08% |
| Q3 2020 | 2020-09-30 | $19,169 | $12,624 | +192.88% |
| Q2 2020 | 2020-06-30 | $19,166 | $15,826 | +473.83% |
| Q1 2020 | 2020-03-31 | $19,171 | $16,977 | +773.79% |
| Q3 2019 | 2019-09-30 | $6,545 | $5,242 | +402.30% |
| Q2 2019 | 2019-06-30 | $3,340 | $2,038 | +156.53% |
| Q1 2019 | 2019-03-31 | $2,194 | −$1,252 | −36.33% |
| Q3 2018 | 2018-09-30 | $1,303 | −$7,239 | −84.75% |
| Q2 2018 | 2018-06-30 | $1,302 | −$7,163 | −84.62% |
| Q1 2018 | 2018-03-31 | $3,446 | −$4,943 | −58.92% |
| Q3 2017 | 2017-09-30 | $8,542 | −$11,796 | −58.00% |
| Q2 2017 | 2017-06-30 | $8,465 | $7,670 | +964.78% |
| Q1 2017 | 2017-03-31 | $8,389 | $7,816 | +1364.05% |
| Q3 2016 | 2016-09-30 | $20,338 | −$8,570 | −29.65% |
| Q2 2016 | 2016-06-30 | $795 | −$32,928 | −97.64% |
| Q1 2016 | 2016-03-31 | $573 | −$32,993 | −98.29% |
| Q3 2015 | 2015-09-30 | $28,908 | −$4,895 | −14.48% |
| Q2 2015 | 2015-06-30 | $33,723 | −$224 | −0.66% |
| Q1 2015 | 2015-03-31 | $33,566 | −$434 | −1.28% |
| Q3 2014 | 2014-09-30 | $33,803 | $32,967 | +3943.42% |
| Q2 2014 | 2014-06-30 | $33,947 | $33,111 | +3960.65% |
| Q1 2014 | 2014-03-31 | $34,000 | $33,345 | +5090.84% |
| Q3 2013 | 2013-09-30 | $836 | $349 | +71.66% |
| Q2 2013 | 2013-06-30 | $836 | $349 | +71.66% |
| Q1 2013 | 2013-03-31 | $655 | $168 | +34.50% |
| Q3 2012 | 2012-09-30 | $487 | $260 | +114.54% |
| Q2 2012 | 2012-06-30 | $487 | $175 | +56.09% |
| Q1 2012 | 2012-03-31 | $487 | $175 | +56.09% |
| Q3 2011 | 2011-09-30 | $227 | — | — |
| Q2 2011 | 2011-06-30 | $312 | — | — |
| Q1 2011 | 2011-03-31 | $312 | — | — |
BioCorRx depreciation and amortization trends
Over the last five fiscal years, BioCorRx's depreciation and amortization decreased from $77,254 to $44,003, a change of −$33,251. The latest reported quarter, Q2 2026, shows $9,834.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioCorRx source filings ↗